๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Venlafaxine ER for the Treatment of Pediatric Subjects With Depression

โœ Scribed by EMSLIE, GRAHAM J.; FINDLING, ROBERT L.; YEUNG, PAUL P.; KUNZ, NADIA R.; LI, YUNFENG

Book ID
125472811
Publisher
Elsevier Science
Year
2007
Tongue
English
Weight
185 KB
Volume
46
Category
Article
ISSN
1527-5418

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Venlafaxine in the treatment of depressi
Venlafaxine in the treatment of depressive and vasomotor symptoms in women with perimenopausal depression
โœ Charlotte O. Ladd; D. Jeffrey Newport; Kimberly A. Ragan; Ada Loughhead; Zachary ๐Ÿ“‚ Article ๐Ÿ“… 2005 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 74 KB ๐Ÿ‘ 1 views

Perimenopause is often marked by vasomotor symptoms and dysphoria. Antidepressant studies have demonstrated decreased frequency and severity of hot flashes in breast cancer survivors and menopausal women. We hypothesized that venlafaxine would relieve both depressive and vasomotor symptoms in depres

The treatment of depression with differe
The treatment of depression with different formulations of venlafaxine: a comparative analysis
โœ James S. Olver; Graham D. Burrows; Trevor R. Norman ๐Ÿ“‚ Article ๐Ÿ“… 2004 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 80 KB ๐Ÿ‘ 1 views

## Abstract Venlafaxine is the first of a group of antidepressants that show dual reuptake inhibition of serotonin and noradrenaline (SNRIs). Originally marketed in an immediate release (IR) formulation a microencapsulated, extended release (XR) formulation is now available. Significant differences